Kent Grindstaff, PhD
SVP Discovery Research
Kent leads BIOAGE’s Discovery Sciences efforts to identify and develop therapies that address age related disease and improve healthspan. With over 20 years of industry experience in drug discovery and operations across a diverse array of therapeutic areas, he brings extensive scientific expertise and management experience to BIOAGE’s preclinical research programs. Kent works closely with our computational sciences, business development, and clinical teams to advance and expand BIOAGE’s portfolio of novel targets, evaluate in-licensing opportunities, and provide translational support for clinical-stage assets. Prior to joining BIOAGE, Kent oversaw discovery research and supported clinical activities at CohBar as VP of Biology, led world-wide client services, project management, and scientific operations as VP Global Operations at Solvo Biotechnology, and severed in various discovery research roles at XenoPort, the most recent as Principal Investigator. Kent received his PhD in Molecular Cell Biology and Biochemistry from Washington University and completed a Senior Post-doctoral Fellowship in the Department of Molecular and Cellular Physiology at Stanford University. He has authored numerous peer-reviewed publications, reviews, grant applications, and patents covering the areas of epithelial differentiation, membrane barriers to drug distribution, active transport mechanisms, and the use of mitochondrial based therapeutics for metabolic and fibrotic diseases.